Jaguar health provides updates on presentation at the world congress of gastroenterology about crofelemer for pediatric short bowel syndrome (sbs) and congenital diarrheal disorders (cdd) by third-party investigator

Jaguar is also supporting a third-party investigator evaluating crofelemer for eosinophilic colitis, another rare pediatric gastrointestinal condition proof-of-concept data for the use of crofelemer for pediatric orphan or rare disorders is expected to provide additional support for the potential for expanded patient access to crofelemer through programs in europe in late 2023 san francisco, ca / accesswire / december 19, 2022 / jaguar health, inc. (nasdaq:jagx) and napo therapeutics, the corporation established by jaguar in italy in 2021 that focuses on expanding crofelemer access for orphan and rare diseases in europe, today announced that an update regarding a third-party clinical investigation of crofelemer for pediatric short bowel syndrome (sbs) and congenital diarrheal disorders (ccd) was presented at the world congress of gastroenterology, a global gi conference that took place december 12-14, 2023 in dubai in the united arab emirates (uae). this update was provided by the clinical investigator, dr. mohamad miqdady, division chief of the pediatric gastroenterology, hepatology & nutrition division at sheikh khalifa medical city in the uae.
JAGX Ratings Summary
JAGX Quant Ranking